List of Excipients in Branded Drug REFISSA

Generic Drugs Containing REFISSA

Company	Ingredient	NDC	Excipient
Suneva Medical Inc	tretinoin	50224-002	BUTYLATED HYDROXYTOLUENE
Suneva Medical Inc	tretinoin	50224-002	CITRIC ACID MONOHYDRATE
Suneva Medical Inc	tretinoin	50224-002	DIMETHICONE
Suneva Medical Inc	tretinoin	50224-002	EDETATE DISODIUM

What are the Most Frequently-Used Excipients in REFISSA?

# Of NDCs	Excipient
1	BUTYLATED HYDROXYTOLUENE
1	CITRIC ACID MONOHYDRATE
1	DIMETHICONE
1	EDETATE DISODIUM

REFISSA Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

REFISSA is a topical tretinoin 0.05% cream indicated for the mitigation of fine facial wrinkles in patients using comprehensive skin-care and sunlight-avoidance programs. Its commercial differentiation is formulation-driven rather than molecule-driven. Tretinoin is an established generic active pharmaceutical ingredient, while the main opportunities involve skin tolerability, physical stability, sensory performance, packaging, lifecycle management, and regulatory positioning.[1]

What is REFISSA and what excipients does it contain?

REFISSA contains tretinoin at a concentration of 0.05% in a topical cream base. The FDA labeling identifies the inactive ingredients as purified water, stearic acid, isopropyl myristate, stearyl alcohol, polyoxyl 40 stearate, xanthan gum, sorbic acid, and butylated hydroxytoluene.[1]

Component	Functional role in REFISSA-type cream	Commercial relevance
Purified water	Continuous aqueous phase	Supports cream texture and ease of application
Stearic acid	Fatty structurant and emollient	Contributes to viscosity, body, and skin feel
Isopropyl myristate	Emollient and spreading agent	Improves slip but may influence acnegenic perception
Stearyl alcohol	Consistency agent and emollient	Builds cream structure and reduces runniness
Polyoxyl 40 stearate	Nonionic emulsifier	Stabilizes the oil-in-water cream system
Xanthan gum	Rheology modifier and suspending aid	Controls viscosity, spreadability, and physical stability
Sorbic acid	Preservative	Supports microbiological control
Butylated hydroxytoluene	Antioxidant	Helps limit oxidative degradation of tretinoin and excipients

The formulation is a conventional emulsion-based delivery system. Its value lies in delivering a poorly water-soluble, light-sensitive retinoid in a cosmetically acceptable vehicle while maintaining dose uniformity and chemical stability.

How does the REFISSA excipient system support tretinoin stability?

Tretinoin is sensitive to light and oxidation. The excipient system therefore has to manage three formulation risks: photodegradation, oxidative degradation, and emulsion instability.

Antioxidant protection

Butylated hydroxytoluene provides oxidative protection. This is important because degradation can reduce potency and generate degradants that may affect product quality. Antioxidant concentration must be optimized against compatibility, regulatory acceptability, and potential irritation.

A reformulator could evaluate alternative antioxidants, including tocopherol derivatives or other approved antioxidants, but substitution would require comparative stability data. A change that improves antioxidant performance may alter odor, color, preservative demand, or skin tolerability.

Emulsion architecture

Stearic acid, stearyl alcohol, polyoxyl 40 stearate, and isopropyl myristate form the principal oil-phase and emulsification system. This combination provides a dense cream with emollient characteristics. The system also creates a potential differentiation point because changes in droplet size, internal phase distribution, and rheology can affect:

• Tretinoin release from the cream.
• Skin deposition.
• Initial irritation.
• Spreadability.
• Residue and greasiness.
• Product uniformity during storage.

A competitor cannot assume that an apparently similar ingredient list will produce equivalent performance. Critical formulation variables include the order of addition, homogenization energy, cooling profile, pH adjustment, shear history, and fill temperature.

Rheology and physical stability

Xanthan gum controls viscosity and can reduce phase separation. Its concentration and hydration process affect yield stress, spreadability, and patient-perceived thickness. Excessive viscosity can reduce adherence, while insufficient viscosity can cause creaming, settling, or inconsistent dosing from the package.

The most commercially attractive target is a cream with controlled yield stress that spreads quickly but does not run or leave a heavy film.

What formulation improvements are commercially available for REFISSA?

The largest opportunities are improved tolerability and consumer usability. Tretinoin is clinically effective but can cause erythema, peeling, dryness, burning, and irritation, particularly during treatment initiation.[1]

Low-irritation cream

A reformulated product could reduce irritation through:

• Smaller and more uniform emulsion droplets.
• Controlled tretinoin release.
• Reduced penetration rate at the skin surface.
• Use of barrier-supportive emollients.
• Lower residual surfactant exposure.
• Optimized pH and water activity.
• Reduced fragrance and sensitizer content.

The product would need to demonstrate that lower irritation does not result from materially lower tretinoin delivery or reduced clinical effectiveness.

Cosmetic elegance

Refissa is positioned in a facial dermatology and aesthetic market where sensory characteristics affect refill behavior. Commercially relevant attributes include:

• Rapid absorption.
• Low tack.
• Low visible whitening.
• Limited greasiness.
• Low odor.
• Compatibility with makeup and sunscreen.
• Easy dosing from the package.

A product with the same 0.05% tretinoin strength can compete through a more acceptable vehicle, particularly if the manufacturer supports the claim with tolerability or patient-preference data.

Alternative delivery systems

Potential delivery platforms include:

1. Microsphere or porous-particle systems that modulate tretinoin release.
2. Lipid-based emulsions that improve skin feel and reduce direct exposure.
3. Hydrogel creams with lower oil content.
4. Water-in-oil or lamellar emulsions for barrier support.
5. Foams, gels, lotions, and serum-like systems.
6. Airless packaging that reduces oxygen and light exposure.
7. Unit-dose or metered-dose systems that improve dosing consistency.

Each platform creates a different regulatory and patent profile. A new vehicle may qualify as a pharmaceutical formulation improvement, but it must establish pharmaceutical equivalence or clinical performance under the applicable FDA pathway.

What patents protect REFISSA and when does it lose exclusivity?

REFISSA contains an established active ingredient, tretinoin, and competes in a market with generic tretinoin products. The commercial protection of a product such as REFISSA is therefore more likely to depend on formulation, packaging, trademark, regulatory exclusivity, and market execution than on basic composition-of-matter protection.

The FDA Orange Book is the principal source for listed patents and exclusivity associated with approved prescription drug products.[2] For topical tretinoin products, the relevant protection questions are:

• Whether the specific REFISSA NDA has active Orange Book-listed patents.
• Whether any listed patent claims the composition, formulation, method of use, or delivery system.
• Whether the patent is enforceable and relevant to a proposed generic.
• Whether the product has current marketing activity.
• Whether an ANDA applicant has submitted a Paragraph IV certification.

A generic applicant may challenge a listed patent through a Paragraph IV certification. The NDA holder may then file infringement litigation within the statutory period, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman framework.[3]

Because generic tretinoin cream products are already established, the principal entry risk is substitution by lower-priced products rather than first-ever generic entry. A new formulation with a distinct vehicle may face a different pathway and could require a 505(b)(2) application if it relies partly on the approved tretinoin product while introducing clinically meaningful formulation differences.[4]

What is the FDA regulatory status of REFISSA?

REFISSA is an FDA-approved prescription topical product containing tretinoin 0.05% cream.[1] The product is regulated as a drug, not as a cosmetic, because its labeling makes therapeutic and dermatologic treatment claims.

A reformulated REFISSA-type product could pursue several regulatory strategies:

Strategy	Likely product profile	Main commercial advantage	Main barrier
ANDA	Generic equivalent to an approved tretinoin cream	Lower development cost and faster route	Limited differentiation and price pressure
505(b)(2) NDA	New vehicle, strength, dosage form, or delivery system	Potential formulation and labeling differentiation	Additional clinical and CMC requirements
New NDA	Materially novel tretinoin product	Broadest commercial positioning	Highest development cost and regulatory burden
OTC cosmetic product	Cosmetic appearance claims without drug claims	Wider consumer access	Cannot use drug-like wrinkle-treatment claims without complying with drug requirements

A product that makes claims about reducing wrinkles, treating acne, or changing skin structure must be assessed against FDA drug-claim requirements. Labeling and promotional language can determine whether a product is treated as a drug rather than a cosmetic.

What formulation patents could protect a new REFISSA product?

The strongest patent strategy would focus on claim elements that are difficult to design around and commercially relevant. Potential claim categories include:

Composition patents

Claims could cover:

• Specific tretinoin concentration ranges.
• Defined antioxidant systems.
• Particular emollient-to-emulsifier ratios.
• Narrow droplet-size distributions.
• Specified pH and viscosity windows.
• Lamellar or multilayer emulsion structures.
• Preservative systems with improved tolerability.

Broad excipient lists are usually vulnerable to design-around strategies. Narrow, performance-linked claims are more defensible when supported by comparative data.

Process patents

Manufacturing claims could cover:

• Controlled temperature addition of tretinoin.
• Low-light or inert-atmosphere processing.
• Specific homogenization conditions.
• Controlled cooling and crystallization.
• In-process oxygen limits.
• Packaging under reduced oxygen exposure.

Process patents are commercially useful when the process produces a measurable quality advantage, such as reduced degradants or improved content uniformity.

Method-of-use patents

Potential claims could address:

• Reduced irritation during treatment initiation.
• Specific dosing schedules.
• Combination use with moisturizers or sunscreen.
• Use in patients with sensitive or dry skin.
• Maintenance regimens after an induction period.
• Treatment of photoaging with improved adherence.

Method-of-use claims require credible clinical support and may be difficult to enforce where generic labels omit the patented use.

Packaging patents

Packaging claims could cover:

• Light-protective tubes.
• Airless pumps.
• Metered-dose dispensers.
• Oxygen-scavenging components.
• Container closure systems that reduce tretinoin degradation.
• Dose counters or controlled-delivery actuators.

Packaging can provide practical differentiation even when the cream composition is similar to generic products.

How strong is the patent estate for REFISSA?

The underlying tretinoin molecule is commercially mature, so a standalone molecule patent is not the principal strategic asset. The strength of a REFISSA-related patent estate depends on whether the claims cover a clinically meaningful formulation advantage and whether competitors can reproduce that advantage using different excipients or process conditions.

Patent asset	Expected strategic value	Design-around risk
Basic tretinoin cream composition	Low to moderate	High
Defined low-irritation formulation	Moderate to high	Moderate
Controlled-release delivery system	High	Moderate
Specialized packaging	Moderate	Moderate to high
Manufacturing process	Moderate	High unless product-by-process evidence is strong
Method of use	Moderate	High if labeling can be carved out
Patient-preference or cosmetic-elegance claims	Commercially useful	Difficult to enforce directly

A defensible estate should combine formulation, manufacturing, packaging, and method-of-use claims. Relying on one broad composition patent would leave substantial room for competitive substitution.

Which companies are challenging or competing with REFISSA?

The competitive field includes manufacturers of generic tretinoin creams, gels, lotions, and microsphere products, as well as branded dermatology companies selling retinoid products and nonprescription retinol products.

The principal competitive groups are:

• Generic manufacturers supplying tretinoin cream 0.025%, 0.05%, and 0.1%.
• Manufacturers of tretinoin microsphere gels and lotions.
• Dermatology companies with branded retinoid portfolios.
• Compounded-product pharmacies.
• Cosmetic brands selling retinol, retinaldehyde, and related vitamin A derivatives.
• Digital dermatology platforms dispensing prescription retinoids.

Competition occurs on price, formulation tolerability, dosage form, access, insurance coverage, packaging, and patient adherence. The branded opportunity is strongest where the product can justify a premium through lower irritation, easier use, superior stability, or a differentiated patient population.

What generic entry risks exist for REFISSA?

Generic substitution presents several risks:

1. Price erosion in the 0.05% tretinoin cream segment.
2. Pharmacy-level substitution where state law and payer policy permit.
3. Loss of prescriber control over the vehicle.
4. Reduced brand visibility.
5. Formulary pressure from low-cost generic products.
6. Patient switching to alternative tretinoin dosage forms.

A generic cream does not need to duplicate every commercial attribute of REFISSA to compete. If it is therapeutically and pharmaceutically equivalent under the applicable FDA requirements, price and distribution can drive substitution.

The strongest defense is a differentiated product with evidence showing better tolerability, improved adherence, or a clinically relevant delivery advantage.

What licensing deals could support a REFISSA lifecycle strategy?

Licensing opportunities exist across four areas:

Excipient and delivery technology

A company could license a proprietary emulsion, microsphere, lipid, or controlled-release platform and apply it to tretinoin. The preferred technology would already have pharmaceutical manufacturing precedent and safety data.

Packaging

An airless or light-protective package could be licensed to improve stability and product presentation. Packaging rights are often easier to secure than rights to a complete drug-delivery platform.

Dermatology commercial partnerships

A specialty-pharma company could license the product to a dermatology commercial organization with established prescriber access. The value of such a transaction would depend on development stage, exclusivity, geographic rights, and reimbursement potential.

Geographic rights

A regional license could support commercialization in markets where topical retinoids have strong prescription demand but limited branded competition. The license should define ownership of formulation improvements, regulatory data, trademarks, and manufacturing changes.

How does REFISSA compare with competing tretinoin products?

Attribute	REFISSA	Generic tretinoin cream	Tretinoin gel or microsphere product	Cosmetic retinol
Active ingredient	Tretinoin 0.05%	Tretinoin, multiple strengths	Tretinoin	Retinol or related derivative
Regulatory category	Prescription drug	Prescription drug	Prescription drug	Usually cosmetic
Main indication positioning	Facial fine wrinkles	Acne and other labeled uses, depending on product	Primarily acne and dermatology uses	Appearance-related cosmetic claims
Formulation differentiation	Cream vehicle	Variable by manufacturer	Gel, lotion, or microsphere system	Broadly variable
Generic substitution risk	High	N/A or product-specific	Moderate	Not directly substitutable
Premium pricing potential	Limited without new evidence	Low	Moderate for differentiated delivery	High in consumer branding
Key development opportunity	Tolerability and cosmetic elegance	Cost and supply	Controlled release and reduced irritation	Consumer experience and claims compliance

REFISSA’s most defensible commercial position is a prescription anti-aging cream with superior tolerability and an established safety and quality profile. It is less defensible as an undifferentiated tretinoin cream competing solely on active ingredient.

What revenue exposure and commercial opportunities exist?

Revenue exposure is concentrated in the prescription facial dermatology market and is sensitive to generic competition. The largest growth opportunities are:

• A low-irritation 0.05% cream for treatment-naive patients.
• A premium formulation for sensitive skin.
• A metered-dose package that improves dosing and hygiene.
• A lower-strength induction product paired with a maintenance regimen.
• A combination product with barrier-supportive ingredients, subject to regulatory requirements.
• A teledermatology product with subscription-based refill access.
• International licensing in markets with growing aesthetic dermatology demand.

The commercial model should distinguish between a low-cost ANDA strategy and a premium 505(b)(2) strategy. An ANDA can capture volume but is exposed to rapid price compression. A 505(b)(2) product can support higher pricing but requires evidence that the formulation provides a meaningful benefit.

Key Takeaways

• REFISSA’s commercial value is formulation-based because tretinoin is an established generic active ingredient.
• Its core excipient system is an oil-in-water cream using fatty alcohols, stearic acid, an emulsifier, xanthan gum, preservative, and antioxidant.
• The strongest development opportunities involve reduced irritation, improved cosmetic feel, light and oxygen protection, and better dosing.
• A new product could pursue an ANDA if it is equivalent or a 505(b)(2) NDA if it introduces a clinically meaningful formulation or delivery change.
• Patent protection should cover formulation composition, manufacturing process, packaging, and method of use rather than rely on broad excipient lists.
• Generic entry and pharmacy substitution create substantial risk for an undifferentiated REFISSA product.
• Premium commercial potential depends on evidence of improved tolerability, adherence, stability, or patient preference.

FAQs

Can REFISSA excipients be copied in a generic tretinoin cream?

A generic product can use similar excipients if it meets applicable pharmaceutical equivalence, quality, stability, and bioequivalence requirements. Similarity alone does not establish infringement of a formulation patent.

Which excipient is most important for tretinoin stability?

Butylated hydroxytoluene is the principal antioxidant identified in the REFISSA labeling. Packaging, light exposure, oxygen exposure, and manufacturing conditions are also important stability controls.

Is isopropyl myristate a commercial risk in facial tretinoin products?

It can affect sensory characteristics and consumer perception of acne-related suitability. Its commercial impact depends on concentration, formulation structure, patient population, and comparative tolerability data.

Could REFISSA be reformulated as a foam or lotion?

Yes. A foam or lotion could create a differentiated dosage form, but the sponsor would need to establish product quality, stability, delivery performance, and the appropriate FDA regulatory pathway.

What is the best patent strategy for a new tretinoin cream?

The strongest strategy combines narrowly defined formulation claims with process, packaging, and method-of-use claims supported by comparative stability, tolerability, and adherence data.

References

1. U.S. Food and Drug Administration. (n.d.). REFISSA (tretinoin) cream, 0.05% prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA guidance and regulatory materials.